A. D. Colevas

910 total citations
24 papers, 652 citations indexed

About

A. D. Colevas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, A. D. Colevas has authored 24 papers receiving a total of 652 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in A. D. Colevas's work include Cancer Treatment and Pharmacology (8 papers), Chronic Lymphocytic Leukemia Research (4 papers) and HER2/EGFR in Cancer Research (4 papers). A. D. Colevas is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Chronic Lymphocytic Leukemia Research (4 papers) and HER2/EGFR in Cancer Research (4 papers). A. D. Colevas collaborates with scholars based in United States. A. D. Colevas's co-authors include Ann Setser, Carolyn Cao, Alan Sandler, David H. Johnson, Ling Geng, Mace L. Rothenberg, Bo Lü, Jennifer A. Low, Hong Wang and Christopher D. Willey and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

A. D. Colevas

24 papers receiving 643 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. D. Colevas United States	10	391	355	113	64	55	24	652
S. Curley United States	8	274 0.7×	287 0.8×	134 1.2×	50 0.8×	50 0.9×	12	606
Yi‐Hung Carol Tan United States	17	255 0.7×	344 1.0×	200 1.8×	56 0.9×	90 1.6×	32	705
Rosario Garrido United States	9	235 0.6×	335 0.9×	222 2.0×	31 0.5×	71 1.3×	11	651
Jennifer A. Grabowsky United States	12	274 0.7×	389 1.1×	104 0.9×	30 0.5×	75 1.4×	29	634
Ainura Kyshtoobayeva United States	13	420 1.1×	441 1.2×	95 0.8×	51 0.8×	192 3.5×	18	859
Mark Morrow United States	13	312 0.8×	392 1.1×	77 0.7×	144 2.3×	151 2.7×	18	661
Sharon Glaysher United Kingdom	16	286 0.7×	324 0.9×	143 1.3×	27 0.4×	112 2.0×	30	690
Anika M. Weber United Kingdom	8	438 1.1×	622 1.8×	134 1.2×	53 0.8×	188 3.4×	12	869
Katie Kane United Kingdom	6	256 0.7×	363 1.0×	101 0.9×	32 0.5×	46 0.8×	9	531

Countries citing papers authored by A. D. Colevas

Since Specialization

Citations

This map shows the geographic impact of A. D. Colevas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. D. Colevas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. D. Colevas more than expected).

Fields of papers citing papers by A. D. Colevas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. D. Colevas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. D. Colevas. The network helps show where A. D. Colevas may publish in the future.

Co-authorship network of co-authors of A. D. Colevas

This figure shows the co-authorship network connecting the top 25 collaborators of A. D. Colevas. A scholar is included among the top collaborators of A. D. Colevas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. D. Colevas. A. D. Colevas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Galloway, Thomas J., Lori J. Wirth, A. D. Colevas, et al.. (2015). A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 21(7). 1566–1573. 84 indexed citations

Bible, Keith C., Prema P. Peethambaram, Ann L. Oberg, et al.. (2012). A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261. Gynecologic Oncology. 127(1). 55–62. 46 indexed citations

He, Aiwu Ruth, Michael J. Pishvaian, A. D. Colevas, et al.. (2010). A phase I study of an oral formulation of ixabepilone (ixa) in patients with advanced cancer.. Journal of Clinical Oncology. 28(15_suppl). e13090–e13090. 2 indexed citations

Eckhardt, S. Gail, G. Gallant, Branimir I. Šikić, et al.. (2010). Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 2580–2580. 8 indexed citations

Cao, Hongyong, Shirley Kwok, Benjamin A. Pinsky, et al.. (2010). Plasma human papillomavirus (HPV) DNA as a potential tool for tumor detection and monitoring response in HPV-related oropharyngeal carcinoma (OP).. Journal of Clinical Oncology. 28(15_suppl). 5529–5529. 1 indexed citations

Waes, Carter Van, Clint Allen, Deborah E. Citrin, et al.. (2009). Molecular and Clinical Responses in a Pilot Study of Gefitinib With Paclitaxel and Radiation in Locally Advanced Head-and-Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 77(2). 447–454. 26 indexed citations

Joseph, Robiya, et al.. (2009). In vivo molecular changes in patients (pts) with metastatic melanoma treated with EMD121974 (selective antagonist of avβ3 integrin). Journal of Clinical Oncology. 27(15_suppl). 9058–9058. 1 indexed citations

Bradley, Deborah, R. Dunn, Charles J. Ryan, et al.. (2007). EMD121974 (NSC 707544, cilengitide) in asymptomatic metastatic androgen independent prostate cancer (AIPCa) patients (pts): A randomized trial by the Prostate Cancer Clinical Trials Consortium (NCI 6372). Journal of Clinical Oncology. 25(18_suppl). 5137–5137. 7 indexed citations

Diwan, A. Hafeez, Nicholas E. Papadopoulos, Agop Y. Bedikian, et al.. (2007). A randomized phase II study of EMD 121974 in patients (pts) with metastatic melanoma (MM). Journal of Clinical Oncology. 25(18_suppl). 8548–8548. 7 indexed citations

10.

Morris, Joel, Clint Allen, Deborah E. Citrin, et al.. (2007). Pilot phase I study of gefitinib (GEF) in combination with paclitaxel (PAC) and radiation therapy (RT) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) and effects on epidermal growth factor receptor (EGFR) signaling pathway. Journal of Clinical Oncology. 25(18_suppl). 16526–16526. 4 indexed citations

11.

Blum, William, Rebecca B. Klisovic, Cheryl Kefauver, et al.. (2006). Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, pharmacokinetics, and pharmacodynamics. Journal of Clinical Oncology. 24(18_suppl). 6568–6568. 2 indexed citations

12.

Heath, Elisabeth I., Amin M. Alousi, Joseph P. Eder, et al.. (2006). A phase I dose escalation trial of ispinesib (SB-715992) administered days 1–3 of a 21-day cycle in patients with advanced solid tumors. Journal of Clinical Oncology. 24(18_suppl). 2026–2026. 16 indexed citations

13.

Posadas, Edwin M., et al.. (2006). A phase II study of ixabepilone (BMS 247550) in metastatic renal cell carcinoma. Journal of Clinical Oncology. 24(18_suppl). 14646–14646. 4 indexed citations

14.

Byrd, John C., T. S. Lin, James T. Dalton, et al.. (2006). Pharmacologically derived schedule of flavopiridol has significant efficacy in refractory, genetically high risk chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. 24(18_suppl). 6516–6516. 7 indexed citations

15.

Fox, Edward, Wendy Goodspeed, Anne Goodwin, et al.. (2005). Phase I trial of the epothilone B analog BMS-247550 (ixabepilone) in children with refractory solid tumors. Journal of Clinical Oncology. 23(16_suppl). 8529–8529. 5 indexed citations

16.

Conley, Barbara A., John C. Morris, A. D. Colevas, et al.. (2005). Proteasome inhibitor bortezomib & re-irradiation (rRT) with scheduled treatment break in patients (pts) with head/neck squamous carcinoma (HNSCC). Journal of Clinical Oncology. 23(16_suppl). 5592–5592. 4 indexed citations

17.

Synold, Timothy W., Robert J. Morgan, Edward M. Newman, et al.. (2005). A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial. Journal of Clinical Oncology. 23(16_suppl). 3036–3036. 61 indexed citations

18.

Lin, Thomas S., James T. Dalton, Di Wu, et al.. (2004). Flavopiridol given as a 30-min intravenous (IV) bolus followed by 4-hr continuous IV infusion (CIVI) results in clinical activity and tumor lysis in refractory chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. 22(14_suppl). 6564–6564. 5 indexed citations

19.

Chen, Tai‐Tsang, A. Molina, Sanjay Goel, et al.. (2004). Epothilone B analog (BMS-247550) at the recommended phase II dose (RPTD) in patients (pts) with gynecologic (gyn) and breast cancers. Journal of Clinical Oncology. 22(14_suppl). 2115–2115. 16 indexed citations

20.

Colevas, A. D. & Ann Setser. (2004). The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. Journal of Clinical Oncology. 22(14_suppl). 6098–6098. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact